Elotuzumab (Empliciti) — CPB 0899 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0899 covering elotuzumab (Empliciti) billing, effective March 3, 2026. Here's what billing teams need to know.

Aetna updated its elotuzumab coverage policy under CPB 0899 Aetna system, expanding recognized indications beyond multiple myeloma to include three plasma cell disorders: POEMS syndrome, plasma cell-related MIDD, and plasma cell-related MGRS. The primary billing code for this drug is J9176 (injection, elotuzumab, 1 mg), and all claims require precertification before treatment begins. If your oncology or hematology billing team handles any of these diagnoses, this change affects your prior authorization workflow and your charge capture immediately.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Elotuzumab (Empliciti) — CPB 0899
Policy Code	CPB 0899
Change Type	Modified
Effective Date	March 3, 2026
Impact Level	Medium — new indications added, precertification required for all
Specialties Affected	Hematology/Oncology, Infusion Centers, Specialty Pharmacy
Key Action	Update prior auth workflows to include POEMS, MIDD, and MGRS as covered indications before billing J9176

---

Aetna Elotuzumab Coverage Criteria and Medical Necessity Requirements 2026

The updated Aetna elotuzumab coverage policy recognizes two categories of approved indications: previously treated multiple myeloma, and three plasma cell disorders — POEMS syndrome, plasma cell-related MIDD (monoclonal immunoglobulin deposition disease), and plasma cell-related MGRS (monoclonal gammopathy of renal significance).

For both categories, Aetna applies identical regimen-based criteria. Elotuzumab must be used in one of three specific combinations to meet medical necessity.

Regimen 1: Elotuzumab with lenalidomide and dexamethasone. Dexamethasone can be billed as J1100 (IV, 1 mg), J8540 (oral, 0.25 mg), or J8541 (Hemady oral, 0.25 mg). Lenalidomide has no specific HCPCS code in this policy.

Regimen 2: Elotuzumab with bortezomib and dexamethasone. Bortezomib has multiple billable codes depending on the manufacturer — J9041 (standard), J9046 (Dr. Reddy's), J9048 (Fresenius Kabi), J9049 (Hospira), J9051 (MAIA), or J9054 (Boruzu). None of these bortezomib variants are therapeutically equivalent to each other per Aetna's coding, so use the manufacturer-specific code on your claim.

Regimen 3: Elotuzumab with pomalidomide and dexamethasone, but only for members who have received at least two prior therapies — including an immunomodulatory agent and a proteasome inhibitor. Pomalidomide also has no specific HCPCS code in this policy.

The real issue here is the regimen specificity. Aetna does not cover elotuzumab as a single agent or in any combination not listed above. If your documentation doesn't clearly reflect one of these three regimens, expect a claim denial.

Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax a Statement of Medical Necessity form to (888) 267-3277 before the first dose. No precertification means no reimbursement — there's no path around this step.

This policy applies to commercial medical plans only. For Medicare patients, Aetna's Medicare Part B criteria govern — check that policy separately before billing J9176 for a Medicare Advantage member.

---

Aetna Elotuzumab Exclusions and Non-Covered Indications

Aetna's position here is direct: any indication not listed in the criteria above is considered experimental, investigational, or unproven.

That means elotuzumab for newly diagnosed multiple myeloma (without prior treatment) is not covered. Elotuzumab as a single agent — not paired with one of the three approved regimens — is not covered. Any off-label use outside of multiple myeloma, POEMS, MIDD, or MGRS is not covered.

The expansion to POEMS, MIDD, and MGRS is notable because these are rare diagnoses. The ICD-10 code landscape for these conditions overlaps with plasma cell disorders and some lymphoma codes — confirm your diagnosis coding matches the covered categories before submitting.

---

Coverage Indications at a Glance

---

Aetna Elotuzumab Billing Guidelines and Action Items 2026

These are the steps your billing team needs to take now — before the effective date of March 3, 2026 has passed and you have claims already in flight.

Copy Action Items

If your practice is new to billing elotuzumab for POEMS, MIDD, or MGRS, talk to your compliance officer before submitting your first claims under these expanded indications. These are rare diagnoses with limited billing precedent — a clean workflow setup now prevents a denial backlog later.

---

CPT, HCPCS, and ICD-10 Codes for Elotuzumab Under CPB 0899

HCPCS Codes Covered When Selection Criteria Are Met

Note on J9047 (carfilzomib): This code appears in the policy's code table but is not referenced in the written approval criteria. Carfilzomib is a proteasome inhibitor — it may be relevant as a prior therapy qualifier for the pomalidomide-based regimen. Don't bill J9047 as part of an elotuzumab regimen without explicit clinical and precertification support.

Note on lenalidomide and pomalidomide: Neither drug has a specific HCPCS code listed in this policy. Both are oral medications typically dispensed through specialty pharmacy. Confirm your billing pathway — these may be billed through the pharmacy benefit rather than the medical benefit, depending on the member's plan design.

Key ICD-10-CM Diagnosis Codes

The policy lists 159 ICD-10-CM codes. The categories most directly relevant to the covered indications are:

The full 159-code list includes additional plasma cell disorder and lymphoma codes not shown in this excerpt. Review the complete CPB 0899 code table on Aetna's site before finalizing your diagnosis coding — especially for POEMS, MIDD, and MGRS, which may map to codes deeper in the list.

---